CRM
67
2
URI
72
3
RF
66
3
DGX
50
4
NWSA
97
8
DFS
68
-2
BBY
43
-2
T
45
4
KSS
39
-4
EXR
60
5
LUV
45
2
WY
56
3
CB
50
4
PDCO
35
-5
ES
31
3
WDC
50
-2
FSLR
41
-5
KMB
30
2
SPG
63
7
KMI
81
2
CRM
67
2
URI
72
3
RF
66
3
DGX
50
4
NWSA
97
8
DFS
68
-2
BBY
43
-2
T
45
4
KSS
39
-4
EXR
60
5
LUV
45
2
WY
56
3
CB
50
4
PDCO
35
-5
ES
31
3
WDC
50
-2
FSLR
41
-5
KMB
30
2
SPG
63
7
KMI
81
2
Financhill
Back

Amphastar Pharmaceuticals 10K Form

Buy
51

AMPH
Amphastar Pharmaceuticals

Last Price:
48.31
Seasonality Move:
5.75%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AMPH News And Ratings

See the #1 stock for the next 7 days that we like better than AMPH

AMPH Financial Statistics

Sales & Book Value

Annual Sales: $644.4M
Cash Flow: $46.17M
Price / Cash Flow: 14.9
Annual Sales: $15.04
Price / Book: 3.19

Profitability

EPS (TTM): 3.00000
Net Income (TTM): $157.72M
Gross Margin: $351.12M
Return on Equity: 23.56%
Return on Assets: 10.28%

Amphastar Pharmaceuticals Earnings Forecast

Key Amphastar Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 21 years for AMPH is 54.49%.
  • The Selling, General & Administrative Expenses for AMPH have been equal to 12.48% of Gross Profit Margin.
  • The Research & Development expenses have been 11.44% of Revenue.
  • The Interest Expense is 19.74% of Operating Income.
  • The Net Earning history of AMPH is 21.34% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 10 years.

Amphastar Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AMPH
CUSIP: 03209R
Website: amphastar.com

Debt

Debt-to-Equity Ratio: 0.82
Current Ratio: 3.43
Quick Ratio: 2.49

Price-to-Earnings

Trailing P/E Ratio: 18.58
Forward P/E Ratio: 11.2

AMPH Technical Analysis vs Fundamental Analysis

Buy
51
Amphastar Pharmaceuticals (AMPH) is a Buy

Is Amphastar Pharmaceuticals a Buy or a Sell?